Free Trial

Aspen Aerogels (ASPN) Financials

Aspen Aerogels logo
$6.43 -0.25 (-3.74%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$6.50 +0.07 (+1.09%)
As of 05/28/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Aspen Aerogels

Annual Income Statements for Aspen Aerogels

This table shows Aspen Aerogels' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
13 -46 -83
Consolidated Net Income / (Loss)
13 -46 -83
Net Income / (Loss) Continuing Operations
13 -46 -83
Total Pre-Tax Income
15 -46 -83
Total Operating Income
55 -49 -79
Total Gross Profit
183 57 4.98
Total Revenue
453 239 180
Operating Revenue
453 239 180
Total Cost of Revenue
270 182 175
Operating Cost of Revenue
270 182 175
Total Operating Expenses
128 106 84
Selling, General & Admin Expense
71 57 38
Marketing Expense
36 33 29
Research & Development Expense
18 16 17
Impairment Charge
3.51 0.00 0.00
Total Other Income / (Expense), net
-39 3.39 -3.49
Interest Expense
35 5.33 5.11
Interest & Investment Income
-4.41 6.53 1.62
Other Income / (Expense), net
0.00 2.19 0.00
Income Tax Expense
1.71 0.00 0.00
Basic Earnings per Share
$0.17 ($0.66) ($2.10)
Weighted Average Basic Shares Outstanding
77.54M 69.44M 39.36M
Diluted Earnings per Share
$0.17 ($0.66) ($2.10)
Weighted Average Diluted Shares Outstanding
80.31M 69.44M 39.36M
Weighted Average Basic & Diluted Shares Outstanding
82.06M 76.66M 70.07M

Quarterly Income Statements for Aspen Aerogels

This table shows Aspen Aerogels' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
12 -13 17 -2.65 -0.52 -13 -15 -17 -9.61 -30
Consolidated Net Income / (Loss)
11 -13 17 -1.84 -0.52 -13 -15 -17 -9.61 -30
Net Income / (Loss) Continuing Operations
12 -13 17 -2.65 -0.52 -13 -15 -17 -9.61 -30
Total Pre-Tax Income
11 -13 18 -1.08 -0.52 -13 -15 -17 -9.61 -30
Total Operating Income
15 17 20 2.44 1.38 -15 -17 -19 -9.67 -28
Total Gross Profit
47 49 52 35 30 14 8.41 5.09 14 -6.36
Total Revenue
123 117 118 95 84 61 48 46 60 37
Operating Revenue
123 117 118 95 84 61 48 46 60 37
Total Cost of Revenue
76 68 66 59 55 47 40 41 45 43
Operating Cost of Revenue
76 68 66 59 55 47 40 41 45 43
Total Operating Expenses
35 32 32 30 28 28 25 24 24 22
Selling, General & Admin Expense
19 18 18 17 15 16 13 12 12 9.96
Marketing Expense
8.55 9.31 9.52 8.30 8.78 8.39 8.13 7.71 7.85 7.29
Research & Development Expense
4.41 4.59 4.57 4.49 4.08 4.22 3.96 4.10 4.20 4.69
Total Other Income / (Expense), net
-0.01 -30 -2.30 -7.03 -1.90 1.56 1.62 2.11 0.06 -1.29
Interest & Investment Income
-3.53 -1.15 0.74 -0.48 1.00 1.31 1.83 2.39 1.06 0.45
Income Tax Expense
-0.18 0.27 0.87 0.76 - 0.00 0.00 0.00 - -
Basic Earnings per Share
$0.14 ($0.17) $0.22 ($0.02) ($0.01) ($0.19) ($0.22) ($0.24) ($0.08) ($0.75)
Weighted Average Basic Shares Outstanding
77.54M 76.26M 76.34M 75.76M 69.44M 69.32M 69.25M 69.16M 39.36M 39.53M
Diluted Earnings per Share
$0.15 ($0.17) $0.21 ($0.02) ($0.01) ($0.19) ($0.22) ($0.24) ($0.08) ($0.75)
Weighted Average Diluted Shares Outstanding
80.31M 76.26M 78.98M 75.76M 69.44M 69.32M 69.25M 69.16M 39.36M 39.53M
Weighted Average Basic & Diluted Shares Outstanding
82.06M 82.05M 77.08M 76.16M 76.66M 70.26M 70.21M 70.11M 70.07M 40.91M

Annual Cash Flow Statements for Aspen Aerogels

This table details how cash moves in and out of Aspen Aerogels' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
81 -143 206
Net Cash From Operating Activities
46 -43 -94
Net Cash From Continuing Operating Activities
46 -43 -94
Net Income / (Loss) Continuing Operations
13 -46 -83
Consolidated Net Income / (Loss)
13 -46 -83
Depreciation Expense
23 15 9.22
Amortization Expense
1.16 0.04 0.03
Non-Cash Adjustments To Reconcile Net Income
57 17 15
Changes in Operating Assets and Liabilities, net
-48 -29 -36
Net Cash From Investing Activities
-86 -175 -178
Net Cash From Continuing Investing Activities
-86 -175 -178
Purchase of Property, Plant & Equipment
-86 -175 -178
Net Cash From Financing Activities
122 75 478
Net Cash From Continuing Financing Activities
122 75 478
Repayment of Debt
-162 0.00 -0.19
Repurchase of Common Equity
0.00 -0.14 -0.14
Issuance of Debt
168 0.00 0.00
Issuance of Common Equity
94 75 390
Other Financing Activities, net
23 0.62 88
Cash Interest Paid
7.01 6.09 2.88

Quarterly Cash Flow Statements for Aspen Aerogels

This table details how cash moves in and out of Aspen Aerogels' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
107 22 -9.84 -38 45 -40 -74 -74 180 -60
Net Cash From Operating Activities
36 21 6.84 -18 -2.78 -7.50 -7.68 -25 -24 -37
Net Cash From Continuing Operating Activities
36 21 6.84 -18 -2.78 -7.48 -7.69 -25 -24 -37
Net Income / (Loss) Continuing Operations
11 -13 17 -1.84 -0.52 -13 -15 -17 -9.61 -30
Consolidated Net Income / (Loss)
11 -13 17 -1.84 -0.52 -13 -15 -17 -9.61 -30
Depreciation Expense
5.43 5.32 5.99 5.79 4.56 4.55 3.50 2.70 2.53 2.53
Amortization Expense
0.84 0.30 0.01 0.01 0.01 0.03 - 0.00 0.01 0.02
Non-Cash Adjustments To Reconcile Net Income
2.58 32 7.13 16 6.17 3.64 3.52 3.26 2.02 5.07
Changes in Operating Assets and Liabilities, net
15 -3.56 -23 -37 -13 -2.62 0.72 -14 -19 -15
Net Cash From Investing Activities
-15 -21 -25 -26 -28 -32 -66 -49 -59 -67
Net Cash From Continuing Investing Activities
-15 -21 -25 -26 -28 -32 -66 -49 -59 -67
Purchase of Property, Plant & Equipment
-15 -21 -25 -26 -28 -32 -66 -49 -59 -67
Net Cash From Financing Activities
86 22 8.14 5.26 76 0.13 0.14 -0.36 263 45
Net Cash From Continuing Financing Activities
86 22 8.14 5.26 76 0.13 0.14 -0.36 263 44
Repayment of Debt
-6.66 -156 - 0.00 - - - 0.00 4.73 -0.19
Repurchase of Common Equity
0.03 - - -0.03 - -0.14 - 0.00 0.63 -0.29
Issuance of Common Equity
94 - - 0.00 75 - - 0.00 267 45
Other Financing Activities, net
-0.75 9.82 8.14 5.29 0.57 0.27 0.14 -0.36 91 -0.00
Cash Interest Paid
4.68 2.31 -0.16 0.19 - 0.96 2.56 2.56 1.47 0.79

Annual Balance Sheets for Aspen Aerogels

This table presents Aspen Aerogels' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
895 703 643
Total Current Assets
409 266 370
Cash & Equivalents
221 140 281
Restricted Cash
0.39 0.25 1.23
Accounts Receivable
109 70 57
Inventories, net
48 39 23
Prepaid Expenses
32 17 7.24
Plant, Property, & Equipment, net
459 417 259
Total Noncurrent Assets
26 19 15
Other Noncurrent Operating Assets
26 19 15
Total Liabilities & Shareholders' Equity
895 703 643
Total Liabilities
280 215 196
Total Current Liabilities
110 78 79
Short-Term Debt
20 0.00 -
Accounts Payable
44 51 55
Accrued Expenses
36 23 16
Current Deferred Revenue
2.20 2.32 5.85
Other Current Liabilities
7.31 1.87 2.37
Total Noncurrent Liabilities
170 137 117
Long-Term Debt
95 0.00 104
Other Noncurrent Operating Liabilities
75 137 13
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
615 488 447
Total Preferred & Common Equity
615 488 447
Preferred Stock
0.00 0.00 0.00
Total Common Equity
615 488 447
Common Stock
1,275 1,162 1,075
Retained Earnings
-660 -674 -628

Quarterly Balance Sheets for Aspen Aerogels

This table presents Aspen Aerogels' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
783 749 698 605 617 621 385
Total Current Assets
306 289 255 200 228 296 156
Cash & Equivalents
113 91 101 95 134 208 102
Restricted Cash
0.39 0.39 0.16 0.32 0.32 0.63 -
Accounts Receivable
115 117 84 54 44 47 27
Inventories, net
47 53 46 34 33 27 21
Prepaid Expenses
29 27 24 17 16 14 6.16
Plant, Property, & Equipment, net
452 438 423 385 368 312 210
Total Noncurrent Assets
25 22 20 20 21 13 19
Other Noncurrent Operating Assets
25 22 20 20 21 13 19
Total Liabilities & Shareholders' Equity
783 749 698 605 617 621 385
Total Liabilities
275 231 207 195 197 188 203
Total Current Liabilities
104 83 64 61 66 69 81
Short-Term Debt
26 - - - - - -
Accounts Payable
42 57 45 37 48 53 58
Accrued Expenses
27 20 13 17 11 9.76 13
Current Deferred Revenue
2.41 3.10 3.13 5.46 4.63 3.97 2.36
Other Current Liabilities
6.83 3.41 2.98 1.99 2.26 2.27 7.54
Total Noncurrent Liabilities
171 147 143 134 131 119 122
Long-Term Debt
94 121 118 112 109 - 105
Other Noncurrent Operating Liabilities
77 26 25 22 22 119 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
508 518 491 410 420 433 182
Total Preferred & Common Equity
508 518 491 410 420 433 182
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
508 518 491 410 420 433 182
Common Stock
1,179 1,176 1,167 1,083 1,080 1,077 801
Retained Earnings
-672 -659 -675 -673 -660 -645 -618

Annual Metrics And Ratios for Aspen Aerogels

This table displays calculated financial ratios and metrics derived from Aspen Aerogels' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
89.64% 32.35% 48.30%
EBITDA Growth
347.06% 54.76% -124.76%
EBIT Growth
215.99% 40.67% -95.19%
NOPAT Growth
240.35% 37.91% -95.19%
Net Income Growth
129.20% 44.63% -123.05%
EPS Growth
125.76% 68.57% -72.13%
Operating Cash Flow Growth
206.89% 54.86% -406.76%
Free Cash Flow Firm Growth
2.07% 58.07% -978.01%
Invested Capital Growth
45.98% 29.66% 417.81%
Revenue Q/Q Growth
9.39% 11.49% 18.48%
EBITDA Q/Q Growth
23.80% 32.53% 8.62%
EBIT Q/Q Growth
32.35% 21.97% 7.74%
NOPAT Q/Q Growth
17.32% 18.34% 7.74%
Net Income Q/Q Growth
795.25% 16.56% 7.54%
EPS Q/Q Growth
1,600.00% 9.59% 17.65%
Operating Cash Flow Q/Q Growth
542.80% 33.33% -14.61%
Free Cash Flow Firm Q/Q Growth
-145.27% 57.29% -26.40%
Invested Capital Q/Q Growth
-1.08% -18.47% 32.86%
Profitability Metrics
- - -
Gross Margin
40.40% 23.84% 2.76%
EBITDA Margin
17.28% -13.26% -38.81%
Operating Margin
12.05% -20.61% -43.94%
EBIT Margin
12.05% -19.70% -43.94%
Profit (Net Income) Margin
2.95% -19.19% -45.87%
Tax Burden Percent
88.64% 100.00% 100.00%
Interest Burden Percent
27.67% 97.44% 104.41%
Effective Tax Rate
11.36% 0.00% 0.00%
Return on Invested Capital (ROIC)
11.29% -11.17% -34.64%
ROIC Less NNEP Spread (ROIC-NNEP)
39.66% -4.04% -13.30%
Return on Net Nonoperating Assets (RNNOA)
-8.87% 1.38% 5.90%
Return on Equity (ROE)
2.43% -9.79% -28.74%
Cash Return on Invested Capital (CROIC)
-26.10% -37.00% -169.89%
Operating Return on Assets (OROA)
6.82% -6.98% -19.18%
Return on Assets (ROA)
1.67% -6.80% -20.02%
Return on Common Equity (ROCE)
2.43% -9.79% -28.74%
Return on Equity Simple (ROE_SIMPLE)
2.18% -9.39% -18.49%
Net Operating Profit after Tax (NOPAT)
48 -34 -55
NOPAT Margin
10.68% -14.43% -30.76%
Net Nonoperating Expense Percent (NNEP)
-28.37% -7.13% -21.34%
Return On Investment Capital (ROIC_SIMPLE)
6.63% -7.06% -10.07%
Cost of Revenue to Revenue
59.60% 76.16% 97.24%
SG&A Expenses to Revenue
15.71% 23.78% 21.35%
R&D to Revenue
3.99% 6.85% 9.39%
Operating Expenses to Revenue
28.35% 44.46% 46.70%
Earnings before Interest and Taxes (EBIT)
55 -47 -79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
78 -32 -70
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.59 2.27 1.08
Price to Tangible Book Value (P/TBV)
1.59 2.27 1.08
Price to Revenue (P/Rev)
2.15 4.64 2.67
Price to Earnings (P/E)
72.88 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
1.37% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.71 2.78 1.13
Enterprise Value to Revenue (EV/Rev)
1.92 4.06 1.68
Enterprise Value to EBITDA (EV/EBITDA)
11.10 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
15.92 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
17.96 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
19.06 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.19 0.00 0.23
Long-Term Debt to Equity
0.15 0.00 0.23
Financial Leverage
-0.22 -0.34 -0.44
Leverage Ratio
1.45 1.44 1.44
Compound Leverage Factor
0.40 1.40 1.50
Debt to Total Capital
15.73% 0.00% 18.80%
Short-Term Debt to Total Capital
2.71% 0.00% 0.00%
Long-Term Debt to Total Capital
13.02% 0.00% 18.80%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
84.27% 100.00% 81.20%
Debt to EBITDA
1.47 0.00 -1.48
Net Debt to EBITDA
-1.36 0.00 2.56
Long-Term Debt to EBITDA
1.21 0.00 -1.48
Debt to NOPAT
2.37 0.00 -1.87
Net Debt to NOPAT
-2.20 0.00 3.23
Long-Term Debt to NOPAT
1.96 0.00 -1.87
Altman Z-Score
2.16 2.19 0.53
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
3.72 3.41 4.68
Quick Ratio
3.00 2.69 4.29
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-112 -114 -272
Operating Cash Flow to CapEx
52.80% -24.29% -53.04%
Free Cash Flow to Firm to Interest Expense
-3.19 -21.41 -53.24
Operating Cash Flow to Interest Expense
1.30 -8.00 -18.47
Operating Cash Flow Less CapEx to Interest Expense
-1.16 -40.93 -53.30
Efficiency Ratios
- - -
Asset Turnover
0.57 0.35 0.44
Accounts Receivable Turnover
5.06 3.75 4.64
Inventory Turnover
6.22 5.89 10.16
Fixed Asset Turnover
1.03 0.71 1.15
Accounts Payable Turnover
5.65 3.44 4.86
Days Sales Outstanding (DSO)
72.20 97.36 78.70
Days Inventory Outstanding (DIO)
58.67 61.97 35.93
Days Payable Outstanding (DPO)
64.57 106.23 75.09
Cash Conversion Cycle (CCC)
66.31 53.09 39.53
Capital & Investment Metrics
- - -
Invested Capital
508 348 268
Invested Capital Turnover
1.06 0.77 1.13
Increase / (Decrease) in Invested Capital
160 80 217
Enterprise Value (EV)
868 969 303
Market Capitalization
975 1,109 482
Book Value per Share
$7.49 $6.95 $10.94
Tangible Book Value per Share
$7.49 $6.95 $10.94
Total Capital
729 488 551
Total Debt
115 0.00 104
Total Long-Term Debt
95 0.00 104
Net Debt
-107 -140 -179
Capital Expenditures (CapEx)
86 175 178
Debt-free, Cash-free Net Working Capital (DFCFNWC)
98 48 8.18
Debt-free Net Working Capital (DFNWC)
319 188 291
Net Working Capital (NWC)
299 188 291
Net Nonoperating Expense (NNE)
35 11 27
Net Nonoperating Obligations (NNO)
-107 -140 -179
Total Depreciation and Amortization (D&A)
24 15 9.25
Debt-free, Cash-free Net Working Capital to Revenue
21.61% 20.22% 4.53%
Debt-free Net Working Capital to Revenue
70.49% 78.85% 161.20%
Net Working Capital to Revenue
66.12% 78.85% 161.20%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.17 ($0.66) ($2.10)
Adjusted Weighted Average Basic Shares Outstanding
77.54M 69.44M 39.36M
Adjusted Diluted Earnings per Share
$0.17 ($0.66) ($2.10)
Adjusted Weighted Average Diluted Shares Outstanding
80.31M 69.44M 39.36M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
82.06M 76.66M 70.07M
Normalized Net Operating Profit after Tax (NOPAT)
51 -34 -55
Normalized NOPAT Margin
11.37% -14.43% -30.76%
Pre Tax Income Margin
3.33% -19.19% -45.87%
Debt Service Ratios
- - -
EBIT to Interest Expense
1.56 -8.82 -15.51
NOPAT to Interest Expense
1.38 -6.46 -10.86
EBIT Less CapEx to Interest Expense
-0.91 -41.76 -50.34
NOPAT Less CapEx to Interest Expense
-1.08 -39.40 -45.68
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -0.30% -0.17%

Quarterly Metrics And Ratios for Aspen Aerogels

This table displays calculated financial ratios and metrics derived from Aspen Aerogels' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
46.15% 93.14% 144.55% 107.30% 41.28% 65.52% 5.52% 18.69% 89.39% 20.82%
EBITDA Growth
252.58% 392.53% 291.88% 129.10% 183.53% 69.44% 34.31% 1.77% 48.08% -174.78%
EBIT Growth
963.85% 239.78% 217.26% 94.29% 114.31% 56.03% 24.74% -1.52% 40.74% -146.21%
NOPAT Growth
1,443.56% 218.90% 259.31% 112.88% 114.31% 48.31% 24.74% -1.52% 40.74% -146.21%
Net Income Growth
2,289.21% 0.79% 209.04% 89.07% 94.60% 55.83% 35.87% 13.80% 41.24% -278.36%
EPS Growth
1,600.00% 10.53% 195.45% 91.67% 87.50% 74.67% 67.65% 59.32% 84.91% -212.50%
Operating Cash Flow Growth
1,384.06% 376.87% 189.10% 28.00% 88.46% 79.97% 23.47% -7.98% -99.85% -519.09%
Free Cash Flow Firm Growth
-84.48% 68.28% 52.95% -75.37% 64.79% -34.40% -216.06% -333.72% -2,611.40% -9,968.39%
Invested Capital Growth
45.98% 20.32% 38.67% 126.24% 29.66% 111.29% 221.95% 191.12% 417.81% 330.58%
Revenue Q/Q Growth
4.90% -0.37% 24.62% 12.21% 38.62% 26.16% 5.64% -23.53% 62.40% -19.57%
EBITDA Q/Q Growth
-8.83% -11.39% 450.93% -20.78% 175.64% 41.88% 16.43% -127.36% 72.33% -24.95%
EBIT Q/Q Growth
-15.44% -12.94% 1,952.27% -178.02% 111.11% 26.97% 9.86% -95.61% 65.86% -25.01%
NOPAT Q/Q Growth
22.69% -35.92% 1,014.67% 76.14% 109.45% 14.14% 9.86% -95.61% 65.86% -25.01%
Net Income Q/Q Growth
187.60% -177.12% 1,016.51% -253.56% 96.03% 15.24% 8.17% -74.79% 67.53% -23.06%
EPS Q/Q Growth
188.24% -180.95% 1,150.00% -100.00% 94.74% 13.64% 8.33% -200.00% 89.33% -10.29%
Operating Cash Flow Q/Q Growth
71.80% 203.54% 138.55% -538.68% 62.96% 2.32% 68.85% -2.37% 35.71% -273.24%
Free Cash Flow Firm Q/Q Growth
-94.59% 44.17% 52.55% -45.38% 66.54% 17.19% -76.86% 28.13% -27.68% -94.75%
Invested Capital Q/Q Growth
-1.08% -6.11% 7.78% 9.62% -18.47% 8.21% 75.84% -16.42% 32.86% 64.88%
Profitability Metrics
- - - - - - - - - -
Gross Margin
38.29% 41.80% 43.80% 37.19% 35.17% 22.73% 17.46% 11.16% 24.05% -17.32%
EBITDA Margin
17.05% 19.62% 22.06% 4.99% 7.07% -12.95% -28.12% -35.55% -11.96% -70.17%
Operating Margin
11.95% 14.83% 16.97% 2.58% 1.64% -24.09% -35.39% -41.48% -16.22% -77.12%
EBIT Margin
11.95% 14.83% 16.97% -1.14% 1.64% -20.49% -35.39% -41.48% -16.22% -77.12%
Profit (Net Income) Margin
9.23% -11.05% 14.28% -1.94% -0.62% -21.52% -32.03% -36.84% -16.12% -80.63%
Tax Burden Percent
101.56% 102.10% 95.10% 170.06% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
76.03% -73.01% 88.48% 100.00% -37.53% 105.02% 90.49% 88.83% 99.41% 104.54%
Effective Tax Rate
-1.56% 0.00% 4.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
12.84% 9.13% 12.25% 1.42% 0.89% -11.48% -18.21% -36.13% -12.78% -66.01%
ROIC Less NNEP Spread (ROIC-NNEP)
15.74% -208.00% -100.89% 5.11% 1.82% -26.86% -7.89% -33.85% -10.56% -40.24%
Return on Net Nonoperating Assets (RNNOA)
-3.52% -5.25% -0.42% -1.06% -0.62% -1.67% 0.91% 17.24% 4.69% 9.40%
Return on Equity (ROE)
9.32% 3.88% 11.83% 0.36% 0.27% -13.15% -17.30% -18.89% -8.10% -56.62%
Cash Return on Invested Capital (CROIC)
-26.10% -9.68% -30.46% -82.72% -37.00% -84.91% -125.22% -134.67% -169.89% -172.91%
Operating Return on Assets (OROA)
6.77% 8.84% 8.88% -0.50% 0.58% -8.86% -13.83% -16.18% -7.08% -40.97%
Return on Assets (ROA)
5.23% -6.59% 7.47% -0.85% -0.22% -9.30% -12.51% -14.37% -7.04% -42.83%
Return on Common Equity (ROCE)
9.32% 3.88% 11.83% 0.36% 0.27% -13.15% -17.30% -18.89% -8.10% -56.62%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.29% 0.27% -6.28% 0.00% -13.40% -17.01% -18.51% 0.00% -49.06%
Net Operating Profit after Tax (NOPAT)
15 12 19 1.71 0.97 -10 -12 -13 -6.77 -20
NOPAT Margin
12.14% 10.38% 16.14% 1.80% 1.15% -16.86% -24.77% -29.03% -11.35% -53.99%
Net Nonoperating Expense Percent (NNEP)
-2.91% 217.13% 113.14% -3.69% -0.93% 15.39% -10.33% -2.28% -2.22% -25.77%
Return On Investment Capital (ROIC_SIMPLE)
2.05% - - - 0.20% - - - -1.23% -
Cost of Revenue to Revenue
61.71% 58.20% 56.20% 62.81% 64.83% 77.27% 82.54% 88.84% 75.95% 117.32%
SG&A Expenses to Revenue
15.16% 15.12% 14.86% 18.21% 18.26% 26.07% 27.74% 26.72% 20.06% 27.14%
R&D to Revenue
3.58% 3.91% 3.88% 4.75% 4.84% 6.94% 8.23% 8.99% 7.04% 12.79%
Operating Expenses to Revenue
28.53% 26.97% 26.83% 31.75% 33.53% 46.82% 52.85% 52.63% 40.26% 59.80%
Earnings before Interest and Taxes (EBIT)
15 17 20 -1.08 1.38 -12 -17 -19 -9.67 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
21 23 26 4.72 5.95 -7.87 -14 -16 -7.13 -26
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.59 4.20 3.51 2.75 2.27 1.47 1.32 1.21 1.08 2.04
Price to Tangible Book Value (P/TBV)
1.59 4.20 3.51 2.75 2.27 1.47 1.32 1.21 1.08 2.04
Price to Revenue (P/Rev)
2.15 5.16 5.08 4.69 4.64 2.82 2.91 2.78 2.67 2.45
Price to Earnings (P/E)
72.88 3,134.22 3,142.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
1.37% 0.03% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.71 4.17 3.37 2.69 2.78 1.45 1.34 1.40 1.13 1.94
Enterprise Value to Revenue (EV/Rev)
1.92 5.17 5.17 4.75 4.06 2.90 2.78 1.67 1.68 2.58
Enterprise Value to EBITDA (EV/EBITDA)
11.10 33.87 61.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
15.92 51.95 201.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
17.96 51.95 201.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
19.06 302.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.19 0.24 0.23 0.24 0.00 0.27 0.26 0.00 0.23 0.67
Long-Term Debt to Equity
0.15 0.18 0.23 0.24 0.00 0.27 0.26 0.00 0.23 0.67
Financial Leverage
-0.22 0.03 0.00 -0.21 -0.34 0.06 -0.12 -0.51 -0.44 -0.23
Leverage Ratio
1.45 1.51 1.46 1.43 1.44 1.67 1.66 1.57 1.44 1.76
Compound Leverage Factor
1.10 -1.10 1.29 1.43 -0.54 1.76 1.51 1.39 1.43 1.84
Debt to Total Capital
15.73% 19.11% 18.95% 19.37% 0.00% 21.48% 20.63% 0.00% 18.80% 40.09%
Short-Term Debt to Total Capital
2.71% 4.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
13.02% 14.93% 18.95% 19.37% 0.00% 21.48% 20.63% 0.00% 18.80% 40.09%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
84.27% 80.89% 81.05% 80.63% 100.00% 78.52% 79.37% 100.00% 81.20% 59.91%
Debt to EBITDA
1.47 1.90 4.02 -12.54 0.00 -2.39 -1.74 0.00 -1.48 -1.59
Net Debt to EBITDA
-1.36 0.10 0.97 -1.74 0.00 -0.36 0.41 0.00 2.56 -0.26
Long-Term Debt to EBITDA
1.21 1.48 4.02 -12.54 0.00 -2.39 -1.74 0.00 -1.48 -1.59
Debt to NOPAT
2.37 2.91 13.20 -6.05 0.00 -2.66 -2.11 0.00 -1.87 -2.03
Net Debt to NOPAT
-2.20 0.15 3.19 -0.84 0.00 -0.41 0.49 0.00 3.23 -0.33
Long-Term Debt to NOPAT
1.96 2.27 13.20 -6.05 0.00 -2.66 -2.11 0.00 -1.87 -2.03
Altman Z-Score
2.01 4.37 4.38 3.30 2.42 0.86 0.72 0.85 0.88 -0.76
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
3.72 2.93 3.46 4.01 3.41 3.27 3.47 4.30 4.68 1.93
Quick Ratio
3.00 2.19 2.50 2.92 2.69 2.43 2.72 3.70 4.29 1.60
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-145 -75 -134 -282 -79 -235 -284 -161 -223 -175
Operating Cash Flow to CapEx
241.91% 99.76% 27.56% -68.63% -10.00% -23.24% -11.63% -49.92% -41.07% -55.91%
Free Cash Flow to Firm to Interest Expense
0.00 -2.58 -43.90 -92.67 -27.09 -121.32 -1,345.62 -583.77 -221.82 -100.89
Operating Cash Flow to Interest Expense
0.00 0.72 2.25 -5.84 -0.96 -3.87 -36.40 -89.64 -23.91 -21.60
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -5.91 -14.36 -10.53 -20.53 -349.25 -269.20 -82.13 -60.23
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.57 0.60 0.52 0.44 0.35 0.43 0.39 0.39 0.44 0.53
Accounts Receivable Turnover
5.06 4.88 4.44 4.38 3.75 5.25 5.16 5.22 4.64 6.64
Inventory Turnover
6.22 6.07 5.26 5.52 5.89 6.27 6.71 8.27 10.16 10.77
Fixed Asset Turnover
1.03 0.99 0.89 0.78 0.71 0.72 0.78 0.96 1.15 1.19
Accounts Payable Turnover
5.65 6.26 4.31 4.11 3.44 3.61 3.40 4.24 4.86 4.79
Days Sales Outstanding (DSO)
72.20 74.80 82.30 83.31 97.36 69.49 70.72 69.88 78.70 54.96
Days Inventory Outstanding (DIO)
58.67 60.12 69.37 66.17 61.97 58.22 54.44 44.16 35.93 33.89
Days Payable Outstanding (DPO)
64.57 58.32 84.63 88.71 106.23 100.99 107.37 86.10 75.09 76.18
Cash Conversion Cycle (CCC)
66.31 76.60 67.04 60.78 53.09 26.73 17.78 27.94 39.53 12.66
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
508 514 547 508 348 427 395 224 268 202
Invested Capital Turnover
1.06 0.88 0.76 0.79 0.77 0.68 0.74 1.24 1.13 1.22
Increase / (Decrease) in Invested Capital
160 87 153 283 80 225 272 147 217 155
Enterprise Value (EV)
868 2,140 1,846 1,366 969 621 528 314 303 393
Market Capitalization
975 2,134 1,816 1,349 1,109 604 553 522 482 373
Book Value per Share
$7.49 $6.59 $6.80 $6.41 $6.95 $5.84 $5.99 $6.17 $10.94 $4.51
Tangible Book Value per Share
$7.49 $6.59 $6.80 $6.41 $6.95 $5.84 $5.99 $6.17 $10.94 $4.51
Total Capital
729 628 639 609 488 522 529 433 551 304
Total Debt
115 120 121 118 0.00 112 109 0.00 104 122
Total Long-Term Debt
95 94 121 118 0.00 112 109 0.00 104 122
Net Debt
-107 6.04 29 16 -140 17 -25 -208 -179 20
Capital Expenditures (CapEx)
15 21 25 26 28 32 66 49 59 67
Debt-free, Cash-free Net Working Capital (DFCFNWC)
98 114 113 90 48 44 28 19 8.18 -27
Debt-free Net Working Capital (DFNWC)
319 228 205 192 188 139 162 227 291 75
Net Working Capital (NWC)
299 202 205 192 188 139 162 227 291 75
Net Nonoperating Expense (NNE)
3.58 25 2.19 3.54 1.49 2.83 3.49 3.56 2.84 9.78
Net Nonoperating Obligations (NNO)
-107 6.04 29 16 -140 17 -25 -208 -179 20
Total Depreciation and Amortization (D&A)
6.28 5.62 6.00 5.80 4.57 4.58 3.50 2.70 2.54 2.55
Debt-free, Cash-free Net Working Capital to Revenue
21.61% 27.53% 31.72% 31.26% 20.22% 20.62% 14.62% 10.15% 4.53% -17.79%
Debt-free Net Working Capital to Revenue
70.49% 55.05% 57.41% 66.59% 78.85% 64.97% 85.45% 121.15% 161.20% 49.48%
Net Working Capital to Revenue
66.12% 48.71% 57.41% 66.59% 78.85% 64.97% 85.45% 121.15% 161.20% 49.48%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.14 ($0.17) $0.22 ($0.02) ($0.01) ($0.19) ($0.22) ($0.24) ($0.08) ($0.75)
Adjusted Weighted Average Basic Shares Outstanding
77.54M 76.26M 76.34M 75.76M 69.44M 69.32M 69.25M 69.16M 39.36M 39.53M
Adjusted Diluted Earnings per Share
$0.15 ($0.17) $0.21 ($0.02) ($0.01) ($0.19) ($0.22) ($0.24) ($0.08) ($0.75)
Adjusted Weighted Average Diluted Shares Outstanding
80.31M 76.26M 78.98M 75.76M 69.44M 69.32M 69.25M 69.16M 39.36M 39.53M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
82.06M 82.05M 77.08M 76.16M 76.66M 70.26M 70.21M 70.11M 70.07M 40.91M
Normalized Net Operating Profit after Tax (NOPAT)
10 12 19 1.71 0.97 -10 -12 -13 -6.77 -20
Normalized NOPAT Margin
8.37% 10.38% 16.14% 1.80% 1.15% -16.86% -24.77% -29.03% -11.35% -53.99%
Pre Tax Income Margin
9.09% -10.83% 15.02% -1.14% -0.62% -21.52% -32.03% -36.84% -16.12% -80.63%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.60 6.57 -0.36 0.48 -6.42 -80.78 -68.76 -9.60 -16.33
NOPAT to Interest Expense
0.00 0.42 6.25 0.56 0.33 -5.29 -56.54 -48.13 -6.72 -11.43
EBIT Less CapEx to Interest Expense
0.00 -0.12 -1.59 -8.87 -9.09 -23.08 -393.63 -248.31 -67.82 -54.96
NOPAT Less CapEx to Interest Expense
0.00 -0.30 -1.91 -7.95 -9.23 -21.94 -369.40 -227.69 -64.94 -50.06
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 1.87% 12.01% -0.54% -0.30% -1.05% -1.01% -0.94% -0.17% -0.87%

Frequently Asked Questions About Aspen Aerogels' Financials

When does Aspen Aerogels's fiscal year end?

According to the most recent income statement we have on file, Aspen Aerogels' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Aspen Aerogels' net income changed over the last 2 years?

Aspen Aerogels' net income appears to be on a downward trend, with a most recent value of $13.38 million in 2024, falling from -$82.74 million in 2022. The previous period was -$45.81 million in 2023. View Aspen Aerogels' forecast to see where analysts expect Aspen Aerogels to go next.

What is Aspen Aerogels's operating income?
Aspen Aerogels's total operating income in 2024 was $54.54 million, based on the following breakdown:
  • Total Gross Profit: $182.90 million
  • Total Operating Expenses: $128.36 million
How has Aspen Aerogels revenue changed over the last 2 years?

Over the last 2 years, Aspen Aerogels' total revenue changed from $180.36 million in 2022 to $452.70 million in 2024, a change of 151.0%.

How much debt does Aspen Aerogels have?

Aspen Aerogels' total liabilities were at $280.44 million at the end of 2024, a 30.4% increase from 2023, and a 43.1% increase since 2022.

How much cash does Aspen Aerogels have?

In the past 2 years, Aspen Aerogels' cash and equivalents has ranged from $139.72 million in 2023 to $281.34 million in 2022, and is currently $220.88 million as of their latest financial filing in 2024.

How has Aspen Aerogels' book value per share changed over the last 2 years?

Over the last 2 years, Aspen Aerogels' book value per share changed from 10.94 in 2022 to 7.49 in 2024, a change of -31.5%.



This page (NYSE:ASPN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners